ClinicalTrials.gg
CompletedNCT02130063ProvideUpdated Sep 27, 2018Results posted

IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose

A Phase 3 interventional study of iron isomaltoside 1000 (Monofer®) and iron sucrose (Venofer®) in Iron Deficiency Anaemia, sponsored by Pharmacosmos A/S. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-27.

Sponsored by Pharmacosmos A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
511
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency — 9 open to participants now, 9 under way, 4 of them phase 3. iron isomaltoside 1000 · Anemia, Iron-Deficiency.

Enrollment
4th of 32
511 · median 121
Started
2014
the only one that year
Phase 3
18 of 32
4 open now
Registered
5th of 32
by date
Lead sponsor
13 of 32
Pharmacosmos A/S

Among the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, this one is the 4th largest by enrollment, is the only one that started in 2014, is one of 18 in phase 3, and was the 5th registered.

Anemia, Iron-Deficiency

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

9 of the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About iron isomaltoside 1000

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

The purpose of the trial is to evaluate and compare the effect of iron isomaltoside 1000 to iron sucrose in its ability to increase haemoglobin (Hb) in subjects with IDA when oral iron preparations are ineffective or cannot be used or where there is a clinical need to deliver iron rapidly.

Read the detailed description

IDA is highly prevalent in subjects with gastrointestinal diseases and cancer, menstruating or pregnant women, and subjects who have undergone bariatric procedure. IDA can have a substantial medical and quality of life (QoL) burden on the subjects and the treatment of these subjects includes controlling the bleeding and replenishing lost iron. Oral iron administration is often used in the clinical practice at many clinics; however, oral iron may not be tolerated by all subjects. Hence, there is a need for an alternative iron treatment in subjects, who do not tolerate oral iron.

This study is planned to compare the efficacy and safety of iron isomaltoside 1000 with another parenteral iron preparation (iron sucrose) in subjects with IDA and who are intolerant or unresponsive to oral iron therapy or who need iron rapidly.

03

Conditions studied

  • Iron Deficiency Anaemia

Keywords

  • IDA
  • Iron deficiency
  • iron deficiency anaemia and who are intolerant or unresponsive to oral iron therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men or women > 18 years having IDA caused by different aetiologies such as abnormal uterine bleeding, gastrointestinal diseases, cancer, bariatric procedures (gastric bypass operations), and other conditions leading to significant blood loss and with a documented history of intolerance or unresponsiveness to oral iron therapy for at least one month prior to study enrollment or where there at investigators judgment is a clinical need to deliver iron rapidly
  2. \< 11 g/dL
  3. TSAT \< 20 %
  4. S-ferritin \< 100 ng/mL
  5. Willingness to participate and signing the form

Exclusion criteria

Exclusion Criteria:

  1. Anaemia predominantly caused by factors other than IDA (e.g. anaemia with untreated vitamin B12 or folate deficiency, haemolytic anaemia)
  2. Iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and haemosiderosis)
  3. Decompensated liver cirrhosis or active hepatitis (ALAT > 3 times )
  4. Active acute or chronic infections (assessed by clinical judgement supplied with white blood cells (WBC) and C-reactive protein (CRP))
  5. Body weight \< 50 kg
  6. Rheumatoid arthritis with symptoms or signs of active inflammation
  7. Pregnant or nursing women. In order to avoid pregnancy, women have to be surgically sterile or use adequate (e.g. intrauterine devices, hormonal contraceptives, or double barrier method) during the whole study period and after the study has ended for at least 5 times plasma biological half-life of the medicinal product
  8. History of multiple allergies
  9. Known to parenteral iron or any in the investigational drug products
  10. Erythropoietin treatment within 8 weeks prior to the screening visit
  11. Other iron treatment or blood transfusion within 4 weeks prior to the screening visit
  12. Planned elective surgery during the study
  13. Participation in any other clinical study within 3 months prior to the screening
  14. Any other medical condition that, in the opinion of Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study, e.g. uncontrolled hypertension, unstable ischaemic heart disease, or uncontrolled diabetes mellitus
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
511 participants (actual)

Study arms

  • Experimental
    iron isomaltoside 1000 (Monofer®)

    iron isomaltoside 1000 (Monofer®)

    Drug: iron isomaltoside 1000 (Monofer®)

  • Active comparator
    iron sucrose (Venofer®)

    iron sucrose (Venofer®)

    Drug: iron sucrose (Venofer®)

06

What researchers measure

Primary outcomes

  1. Number of Subjects With an Haemoglobin (Hb) Increase of ≥ 2 g/dL From Baseline at Any Time From Week 1 to Week 5

    The primary efficacy endpoint of the trial was the count of subjects with an Hb increase of ≥ 2 g/dL from baseline at any time from week 1 to week 5. 'Any time' implied that if the endpoint was met at a time-point prior to or at week 5, the effect (increase of ≥ 2 g/dL) did not have to be maintained throughout the trial in order for a subject to be a responder. Number of responders (i.e. a subject with increase in Hb ≥ 2 g/dL from baseline at any time from week 1 to week 5) and percentages according to number of subjects in the analysis set were summarised.

    Time frame: From baseline to week 5

Secondary outcomes

  1. Change in Hb Concentration

    Time frame: From baseline to week 2, 4 and 5

  2. Change in Serum (s)-Ferritin Concentration

    Time frame: From baseline to week 1, 2, 4, and 5

  3. Change in Transferrin Saturation (TSAT)

    Time frame: From baseline to week 1, 2, 4, and 5

07

Results

Posted May 22, 2018

Participant flow

Participant flow — Overall Study
MilestoneIron Isomaltoside 1000 (Monofer®)Iron Sucrose (Venofer®)
Started342169
Completed317152
Not completed2517

Outcome measures

PrimaryNumber of Subjects With an Haemoglobin (Hb) Increase of ≥ 2 g/dL From Baseline at Any Time From Week 1 to Week 5

The primary efficacy endpoint of the trial was the count of subjects with an Hb increase of ≥ 2 g/dL from baseline at any time from week 1 to week 5. 'Any time' implied that if the endpoint was met at a time-point prior to or at week 5, the effect (increase of ≥ 2 g/dL) did not have to be maintained throughout the trial in order for a subject to be a responder. Number of responders (i.e. a subject with increase in Hb ≥ 2 g/dL from baseline at any time from week 1 to week 5) and percentages according to number of subjects in the analysis set were summarised.

Time frame:
From baseline to week 5
Reported as:
Number · participants
Number of Subjects With an Haemoglobin (Hb) Increase of ≥ 2 g/dL From Baseline at Any Time From Week 1 to Week 5
participantsIron Isomaltoside 1000 (Monofer®)Iron Sucrose (Venofer®)
Number of Subjects With an Haemoglobin (Hb) Increase of ≥ 2 g/dL From Baseline at Any Time From Week 1 to Week 522683
SecondaryChange in Hb Concentration
Time frame:
From baseline to week 2, 4 and 5
Reported as:
Mean · g/dL
Change in Hb Concentration
g/dLIron Isomaltoside 1000 (Monofer®)Iron Sucrose (Venofer®)
Week 21.56 ± 1.030.87 ± 0.90
Week 42.35 ± 1.321.74 ± 1.17
Week 52.52 ± 1.412.05 ± 1.27
SecondaryChange in Serum (s)-Ferritin Concentration
Time frame:
From baseline to week 1, 2, 4, and 5
Reported as:
Mean · ng/mL
Change in Serum (s)-Ferritin Concentration
ng/mLIron Isomaltoside 1000 (Monofer®)Iron Sucrose (Venofer®)
Week 1431.2 ± 221.486.9 ± 84.8
Week 2516.6 ± 268.1126.2 ± 87.2
Week 4285.3 ± 205.2195.0 ± 126.2
Week 5241.2 ± 209.3185.7 ± 166.8
SecondaryChange in Transferrin Saturation (TSAT)
Time frame:
From baseline to week 1, 2, 4, and 5
Reported as:
Mean · percent
Change in Transferrin Saturation (TSAT)
percentIron Isomaltoside 1000 (Monofer®)Iron Sucrose (Venofer®)
Week 115.7 ± 9.63.3 ± 8.1
Week 217.9 ± 9.85.7 ± 6.8
Week 416.3 ± 9.011.5 ± 9.5
Week 515.6 ± 8.611.8 ± 9.5

Adverse events

Collected over From screening until week 5. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Iron Isomaltoside 1000 (Monofer®)1/333 (0.3%)11/333 (3.3%)100/333 (30%)
Iron Sucrose (Venofer®)0/168 (0%)6/168 (3.6%)54/168 (32.1%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventIron Isomaltoside 1000 (Monofer®)Iron Sucrose (Venofer®)
Vertigo positionalEar and labyrinth disorders0/3331/168
Stent malfunctionGeneral disorders0/3331/168
Anaphylactic reactionImmune system disorders0/3331/168
Postpartum haemorrhagePregnancy, puerperium and perinatal conditions0/3331/168
AsthmaRespiratory, thoracic and mediastinal disorders0/3331/168
AnaemiaBlood and lymphatic system disorders0/3331/168
Cardiac failure congestiveCardiac disorders1/3330/168
Cardio-respiratory arrestCardiac disorders1/3330/168
DiarrhoeaGastrointestinal disorders1/3330/168
EnteritisGastrointestinal disorders1/3330/168
Most frequent other events
Showing 10 of 12
Most frequent other events
EventIron Isomaltoside 1000 (Monofer®)Iron Sucrose (Venofer®)
HeadacheNervous system disorders18/33311/168
NauseaGastrointestinal disorders17/3337/168
RashSkin and subcutaneous tissue disorders14/3331/168
Upper respiratory tract infectionInfections and infestations4/3336/168
VomitingGastrointestinal disorders7/3335/168
DiarrhoeaGastrointestinal disorders3/3335/168
DysgeusiaNervous system disorders2/3335/168
FatiqueGeneral disorders4/3335/168
DizzinessNervous system disorders9/3334/168
Back painMusculoskeletal and connective tissue disorders8/3332/168

Baseline characteristics

FAS (N = 491): The FAS consisted of all subjects who were randomised, received at least one dose of the trial drug, and had at least one post-baseline Hb assessment.

Age, Continuous
Age, Continuous(years)Iron Isomaltoside 1000 (Monofer®)Iron Sucrose (Venofer®)Total
Mean49.3 ± 15.846.8 ± 14.948.4 ± 15.6
Sex: Female, Male
Sex: Female, Male(Participants)Iron Isomaltoside 1000 (Monofer®)Iron Sucrose (Venofer®)Total
Female309154463
Male331548
Region of Enrollment
Region of Enrollment(participants)Iron Isomaltoside 1000 (Monofer®)Iron Sucrose (Venofer®)Total
United States342169511
08

Study locations

1 site
  • Wilmington, Delaware, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2018, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2014
First posted
May 2, 2014
Start
May 2014
Primary completionActual
Aug 2015
CompletionActual
Aug 2015
Results first posted
May 22, 2018
Last update
Sep 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02130063
Lead sponsor
Pharmacosmos A/S
Collaborators
BioStata, ClinStar, LLC, Laboratory Corporation of America
Responsible party
Sponsor
First posted
May 2, 2014
Start date
May 2014
Primary completion
Aug 2015
Completion
Aug 2015
Results posted
May 22, 2018
Last update
Sep 27, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron isomaltoside 1000

Start the discussion